Literature DB >> 23065512

Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts.

Véronique Gelsi-Boyer1, Nathalie Cervera, François Bertucci, Mandy Brecqueville, Pascal Finetti, Anne Murati, Christine Arnoulet, Marie-Joelle Mozziconacci, Ken I Mills, Nicholas C P Cross, Norbert Vey, Daniel Birnbaum.   

Abstract

Chronic myelomonocytic leukemia is similar to but a separate entity from both myeloproliferative neoplasms and myelodysplastic syndromes, and shows either myeloproliferative or myelodysplastic features. We ask whether this distinction may have a molecular basis. We established the gene expression profiles of 39 samples of chronic myelomonocytic leukemia (including 12 CD34-positive) and 32 CD34-positive samples of myelodysplastic syndromes by using Affymetrix microarrays, and studied the status of 18 genes by Sanger sequencing and array-comparative genomic hybridization in 53 samples. Analysis of 12 mRNAS from chronic myelomonocytic leukemia established a gene expression signature of 122 probe sets differentially expressed between proliferative and dysplastic cases of chronic myelomonocytic leukemia. As compared to proliferative cases, dysplastic cases over-expressed genes involved in red blood cell biology. When applied to 32 myelodysplastic syndromes, this gene expression signature was able to discriminate refractory anemias with ring sideroblasts from refractory anemias with excess of blasts. By comparing mRNAS from these two forms of myelodysplastic syndromes we derived a second gene expression signature. This signature separated the myelodysplastic and myeloproliferative forms of chronic myelomonocytic leukemias. These results were validated using two independent gene expression data sets. We found that myelodysplastic chronic myelomonocytic leukemias are characterized by mutations in transcription/epigenetic regulators (ASXL1, RUNX1, TET2) and splicing genes (SRSF2) and the absence of mutations in signaling genes. Myelodysplastic chronic myelomonocytic leukemias and refractory anemias with ring sideroblasts share a common expression program suggesting they are part of a continuum, which is not totally explained by their similar but not, however, identical mutation spectrum.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23065512      PMCID: PMC3685272          DOI: 10.3324/haematol.2012.071506

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  48 in total

1.  Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.

Authors:  Francesco Onida; Hagop M Kantarjian; Terry L Smith; Greg Ball; Michael J Keating; Elihu H Estey; Armand B Glassman; Maher Albitar; Monica I Kwari; Miloslav Beran
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

2.  The gata1/pu.1 lineage fate paradigm varies between blood populations and is modulated by tif1γ.

Authors:  Rui Monteiro; Claire Pouget; Roger Patient
Journal:  EMBO J       Date:  2011-02-18       Impact factor: 11.598

3.  Molecular basis of myelodysplastic/myeloproliferative neoplasms.

Authors:  Andreas Reiter; Rosangela Invernizzi; Nicholas C P Cross; Mario Cazzola
Journal:  Haematologica       Date:  2009-12       Impact factor: 9.941

4.  Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.

Authors:  Frederik Damm; Olivier Kosmider; Véronique Gelsi-Boyer; Aline Renneville; Nadine Carbuccia; Claire Hidalgo-Curtis; Véronique Della Valle; Lucile Couronné; Laurianne Scourzic; Virginie Chesnais; Agnes Guerci-Bresler; Bohrane Slama; Odile Beyne-Rauzy; Aline Schmidt-Tanguy; Aspasia Stamatoullas-Bastard; François Dreyfus; Thomas Prébet; Stéphane de Botton; Norbert Vey; Michael A Morgan; Nicholas C P Cross; Claude Preudhomme; Daniel Birnbaum; Olivier A Bernard; Michaela Fontenay
Journal:  Blood       Date:  2012-02-17       Impact factor: 22.113

5.  SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes.

Authors:  Valeria Visconte; Heesun J Rogers; Jarnail Singh; John Barnard; Manoj Bupathi; Fabiola Traina; James McMahon; Hideki Makishima; Hadrian Szpurka; Anna Jankowska; Andres Jerez; Mikkael A Sekeres; Yogen Saunthararajah; Anjali S Advani; Edward Copelan; Haruhiko Koseki; Kyoichi Isono; Richard A Padgett; Sami Osman; Kazunori Koide; Christine O'Keefe; Jaroslaw P Maciejewski; Ramon V Tiu
Journal:  Blood       Date:  2012-07-23       Impact factor: 22.113

6.  Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.

Authors:  Anna M Jankowska; Hideki Makishima; Ramon V Tiu; Hadrian Szpurka; Yun Huang; Fabiola Traina; Valeria Visconte; Yuka Sugimoto; Courtney Prince; Christine O'Keefe; Eric D Hsi; Alan List; Mikkael A Sekeres; Anjana Rao; Michael A McDevitt; Jaroslaw P Maciejewski
Journal:  Blood       Date:  2011-08-09       Impact factor: 22.113

7.  Clinical effect of point mutations in myelodysplastic syndromes.

Authors:  Rafael Bejar; Kristen Stevenson; Omar Abdel-Wahab; Naomi Galili; Björn Nilsson; Guillermo Garcia-Manero; Hagop Kantarjian; Azra Raza; Ross L Levine; Donna Neuberg; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2011-06-30       Impact factor: 91.245

8.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

9.  Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers.

Authors:  François Bertucci; Pascal Finetti; Nathalie Cervera; Emmanuelle Charafe-Jauffret; Emilie Mamessier; José Adélaïde; Stéphane Debono; Gilles Houvenaeghel; Dominique Maraninchi; Patrice Viens; Colette Charpin; Jocelyne Jacquemier; Daniel Birnbaum
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

10.  Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.

Authors:  Véronique Gelsi-Boyer; Virginie Trouplin; José Adélaïde; Julien Bonansea; Nathalie Cervera; Nadine Carbuccia; Arnaud Lagarde; Thomas Prebet; Meyer Nezri; Danielle Sainty; Sylviane Olschwang; Luc Xerri; Max Chaffanet; Marie-Joëlle Mozziconacci; Norbert Vey; Daniel Birnbaum
Journal:  Br J Haematol       Date:  2009-04-15       Impact factor: 6.998

View more
  4 in total

1.  A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction.

Authors:  Rami S Komrokji; Adam W Mailloux; Dung-Tsa Chen; Mikkael A Sekeres; Ronald Paquette; William J Fulp; Chiharu Sugimori; Jennifer Paleveda-Pena; Jaroslaw P Maciejewski; Alan F List; Pearlie K Epling-Burnette
Journal:  Haematologica       Date:  2014-01-31       Impact factor: 9.941

2.  Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation.

Authors:  Robert R West; Amy P Hsu; Steven M Holland; Jennifer Cuellar-Rodriguez; Dennis D Hickstein
Journal:  Haematologica       Date:  2013-09-27       Impact factor: 9.941

3.  Evolution of chronic myelomonocytic leukemia from refractory anemia: the unusual course of a myelodysplastic syndrome.

Authors:  Pasquale Niscola; Andrea Tendas; Laura Scaramucci; Marco Giovannini; Stefano Fratoni; Paolo de Fabritiis
Journal:  Blood Res       Date:  2013-06-25

4.  Chronic myelomonocytic leukaemia stem cell transcriptomes anticipate disease morphology and outcome.

Authors:  Daniel H Wiseman; Syed M Baker; Arundhati V Dongre; Kristian Gurashi; Joanna A Storer; Tim Cp Somervaille; Kiran Batta
Journal:  EBioMedicine       Date:  2020-08-04       Impact factor: 8.143

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.